ERBB2 and breast carcinoma: Among them, 2474 HER2-negative metastatic breast cancer patients were used in this pooled analysis, excluding patients not receiving bevacizumab plus paclitaxel as first-line chemotherapy (n = 279), locally advanced or local recurrent breast cancer without distant metastasis (n = 184), and patients with other reason for ineligibility (n = 13) (Supplementary Fig. 1).